PriceSensitive

Dundee Corporation (TSX:DC.A) portfolio holding, TauRx Pharmaceuticals secures funding for regulatory submissions of its Alzheimer’s treatment

Finance, Health Care, The Watchlist
TSX:DC.A
16 November 2022 13:00 (EDT)

This browser does not support the video element.

Dundee Corporation (DC.A) portfolio holding, TauRx Pharmaceuticals, has raised US$119 million through a warrant exercise.

The proceeds will fund TauRx’s regulatory submissions in the UK, US and Canada and advance development plans for regulatory approval in China.

President and CEO Jonathan Goodman sat down with Sabrina Cuthbert to discuss the news. “We are extremely pleased to learn that TauRx was successful in its efforts to secure the necessary funding to undergo regulatory submissions of its promising Alzheimer’s treatment in 2023. We wish the company well in these efforts and look forward to its presentation of results of its LUCIDITY trial at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco on November 30th.”

TauRx announcement highlights:

Dundee holds 1,015,008 shares in TauRx, representing a 3.2 per cent interest in the company.

Dundee Corporation is a Canadian independent holding company. Through its operating subsidiaries, Dundee Corporation is an active investor focused on delivering long-term, sustainable value as a trusted partner in the mining sector with more than 30 years of experience making accretive mining investments.

Dundee Corporation (DC.A) opened trading at C$1.37.


Related News